Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 75

Erector spinae plane blocks to reduce pain after cervical or lumbar spinal fusion

Official title: A Double-Blind Prospective RCT Assessment of ESP Blocks for Analgesia Following Posterior Spinal Fusion

Run by Duke University · NCT07228039 · Data updated 2026-11-12

This trial tests whether an ESP block with bupivacaine (with or without liposomal bupivacaine) can lower pain and opioid use after cervical or lumbar posterior spinal fusion in adults.

More Postoperative Pain trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment75 (estimated)
SponsorDuke University
Academic / other
Locations1 site (Durham, North Carolina)
StatusRecruiting
StartedSeptember 17, 2026
Main results expectedJanuary 2028
Study endsJanuary 2028
Registry record updatedNovember 6, 2026
Trial IDNCT07228039 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–75 undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels), English-speaking, ASA I–III, without contraindications to ESP block or study drugs.

Probably not a fit

Patients with contraindications to regional anesthesia, higher ASA status (IV–V), or who do not respond to ESP block may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, double-blind study comparing two ESP block regimens in adults undergoing elective cervical or lumbar posterior fusion (up to 3 levels). Participants receive either 0.5% plain bupivacaine or 0.5% bupivacaine plus liposomal bupivacaine for postoperative analgesia. Primary outcomes include opioid consumption over 72 hours, with secondary measures such as pain scores, length of stay, and time to ambulation. The trial is conducted at Duke University and aims to clarify whether adding liposomal bupivacaine provides superior analgesia and recovery benefits. Eligible patients are English-speaking adults aged 18–75, ASA I–III, without contraindications to regional anesthesia or study drugs.

Why it matters

Potential benefit: If successful, patients may experience less pain and faster recovery after spine surgery due to improved regional analgesia.

How similar studies have gone: Previous regional analgesia studies for spine surgery have shown meaningful pain reduction, though results vary by technique and regimen; this specific ESP block comparison is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* English speaking
* Age 18-75
* ASA physical status 1-3
* Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)

Exclusion Criteria

* Age \<18 or \>75
* ASA IV or V
* Non-English speaking
* BMI \>40
* Opioid dependence
* Chronic pain
* Anticoagulation or coagulopathy
* Injection site infection
* Hepatic or renal insufficiency
* Allergy to study drugs
* Pregnancy
* Inability to communicate with investigators

Where it's running

  • Duke University
    Durham, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Stephen Davies — Duke University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.